TY - JOUR
T1 - The detection of IRF-1 promoter polymorphisms and their possible contribution to T helper 1 response in chronic hepatitis C
AU - Saito, Hidetsugu
AU - Tada, Shinichiro
AU - Wakabayashi, Kanji
AU - Nakamoto, Nobuhiro
AU - Takahashi, Masahiko
AU - Nakamura, Mitsuyasu
AU - Ebinuma, Hirotoshi
AU - Ishii, Hiromasa
PY - 2002/9/27
Y1 - 2002/9/27
N2 - We described the interferon (IFN) regulatory factor-1 (IRF-1) promoter single nucleotide polymorphisms (SNPs), and the clinical and immunologic implications of these SNPs have been investigated. We successfully determined the mutation at -300 of the IRF-1 promoter by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and this mutation linked with other mutations in the promoter region. In our Japanese population, the frequency of the type -300*A/A was 11.9%, type A/G was 54.2%, and type G/G was 33.9%. We found no significant difference without IFN stimulation in the production levels of IFN-γ and interleukin-10 (IL-10) from peripheral blood mononuclear cells (PBMC) between subjects with -300*A/A and those with other types. IFN-α stimulation, however, increased the levels of IFN-γ significantly and decreased the IL-10 production level significantly only in the subject with -300*A/A type. Flow cytometric analysis showed that the Th1-type CD4+ cell population was significantly increased by IFN-β administration only in the patient with chronic hepatitis C with -300*A/A type. These results suggest that the IRF-1 promoter SNP types are positively involved in Th1-type response and, consequently, the -300*A/A type may be beneficial for viral elimination in chronic hepatitis C and IFN therapy.
AB - We described the interferon (IFN) regulatory factor-1 (IRF-1) promoter single nucleotide polymorphisms (SNPs), and the clinical and immunologic implications of these SNPs have been investigated. We successfully determined the mutation at -300 of the IRF-1 promoter by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and this mutation linked with other mutations in the promoter region. In our Japanese population, the frequency of the type -300*A/A was 11.9%, type A/G was 54.2%, and type G/G was 33.9%. We found no significant difference without IFN stimulation in the production levels of IFN-γ and interleukin-10 (IL-10) from peripheral blood mononuclear cells (PBMC) between subjects with -300*A/A and those with other types. IFN-α stimulation, however, increased the levels of IFN-γ significantly and decreased the IL-10 production level significantly only in the subject with -300*A/A type. Flow cytometric analysis showed that the Th1-type CD4+ cell population was significantly increased by IFN-β administration only in the patient with chronic hepatitis C with -300*A/A type. These results suggest that the IRF-1 promoter SNP types are positively involved in Th1-type response and, consequently, the -300*A/A type may be beneficial for viral elimination in chronic hepatitis C and IFN therapy.
UR - http://www.scopus.com/inward/record.url?scp=0036376634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036376634&partnerID=8YFLogxK
U2 - 10.1089/10799900260100196
DO - 10.1089/10799900260100196
M3 - Article
C2 - 12162881
AN - SCOPUS:0036376634
SN - 1079-9907
VL - 22
SP - 693
EP - 700
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 6
ER -